Tresiba Flextouch Pen

Tresiba Flextouch Pen

Tresiba Flextouch Pen is a long-acting insulin delivery device containing insulin degludec, used for the management of diabetes mellitus (type 1 and type 2). It provides ultra-long blood sugar control lasting more than 24 hours, helping maintain stable glucose levels throughout the day and night. This pre-filled pen is designed for convenient and accurate dosing. It is commonly prescribed when oral medications are not sufficient for glycemic control. In diabetes management, therapies like Sitagliptin Tablets 50 Mg and combination options such as Sitagliptin & Metformin Tablets 50/500 Mg are often used alongside insulin therapy.

Mechanism of Action

Ultra-Long Acting Insulin

Tresiba contains insulin degludec, which forms a depot under the skin and releases insulin slowly over time.

Stable Glucose Control

It provides a steady insulin level, reducing blood sugar fluctuations and improving fasting glucose control. For clinical insights, refer to American Diabetes Association (ADA) and for safety guidance, consult Mayo Clinic – Insulin Degludec Information.

Medical Uses

Tresiba Flextouch Pen is used for:

• Type 1 diabetes mellitus
• Type 2 diabetes mellitus
• Basal insulin therapy
• Long-term blood sugar control

It is widely used for consistent and flexible insulin management.

Dosage and Administration

Tresiba Flextouch Pen is injected subcutaneously once daily, at any time of the day (preferably the same time), as directed by a healthcare provider. The dose is individualized based on blood sugar levels and patient needs. In clinical practice, Sitagliptin Tablets 50 Mg and Sitagliptin & Metformin Tablets 50/500 Mg may be used alongside insulin for improved glycemic control.

Clinical Effectiveness

Clinical studies show that insulin degludec provides stable, long-lasting blood sugar control with a lower risk of hypoglycemia compared to some other long-acting insulins.

Safety and Side Effects

Common Side Effects

• Hypoglycemia (low blood sugar)
• Injection site reactions
• Weight gain

Serious Risks

• Severe hypoglycemia
• Allergic reactions

Regular blood glucose monitoring is essential. For more details, refer to Mayo Clinic – Insulin Degludec Information.

Contraindications and Precautions

Tresiba Flextouch Pen should be used with caution in:

• Patients prone to hypoglycemia
• Individuals with kidney or liver disease
• Pregnant or breastfeeding women

Medical supervision is required for safe use.

Drug Interactions

Tresiba may interact with other antidiabetic medications, increasing the risk of hypoglycemia. Patients should inform their healthcare provider about all medicines they are taking. For further reading, refer to American Diabetes Association (ADA).

FAQs